BackOno Pharmaceutical , Ltd. Overview

Ono Pharmaceutical , Ltd. Profit Margin

Latest profit margin for Ono Pharmaceutical , Ltd.: 15.17% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

17.86%
↑ 2.88% YoY

As of Sep 2026

Annual Profit Margin (TTM)

15.17%
↑ 56.80% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Ono Pharmaceutical , Ltd. (OPHLF) FAQ

Ono Pharmaceutical , Ltd. posts a profit margin of 15.17% as of September 2026. That compares with 9.67% in the prior-year period — up 56.8% year over year. That is above the sector sector average of 13.4%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Ono Pharmaceutical , Ltd.'s profit margin was 9.67%. The latest reading is 15.17% — a 56.8% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.4% is typical. Ono Pharmaceutical , Ltd.'s 15.17% is higher that level. That is roughly 13.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Ono Pharmaceutical , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 15.17% as of September 2026; use YoY and peer views to separate noise from signal.

Context for OPHLF's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.4%), and (3) consistency with growth and profitability. This page covers the first two; Ono Pharmaceutical , Ltd.'s other metric pages and overview cover the third.